Anthera Pharmaceuticals, Inc. (ANTH)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | 36.53 Million USD | -36.27% |
| 2016 | 57.32 Million USD | 49.17% |
| 2015 | 38.42 Million USD | 35.03% |
| 2014 | 28.45 Million USD | 0.75% |
| 2013 | 28.24 Million USD | -49.5% |
| 2012 | 55.93 Million USD | -39.95% |
| 2011 | 93.13 Million USD | 160.47% |
| 2010 | 35.75 Million USD | 201.98% |
| 2009 | 11.84 Million USD | -14.58% |
| 2008 | 13.86 Million USD | -47.47% |
| 2007 | 26.39 Million USD | 207.58% |
| 2006 | 8.58 Million USD | 1460.0% |
| 2005 | 550 Thousand USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2018 Q1 | 10.97 Million USD | 18.54% |
| 2017 Q2 | 8.65 Million USD | -19.11% |
| 2017 Q3 | 7.91 Million USD | -8.6% |
| 2017 Q4 | 9.25 Million USD | 16.94% |
| 2017 FY | 36.53 Million USD | -36.27% |
| 2017 Q1 | 10.7 Million USD | -26.58% |
| 2016 FY | 57.32 Million USD | 49.17% |
| 2016 Q1 | 11.86 Million USD | 27.44% |
| 2016 Q2 | 14.28 Million USD | 20.39% |
| 2016 Q3 | 16.6 Million USD | 16.24% |
| 2016 Q4 | 14.57 Million USD | -12.17% |
| 2015 Q3 | 12.08 Million USD | 32.27% |
| 2015 Q2 | 9.13 Million USD | 15.6% |
| 2015 FY | 38.42 Million USD | 35.03% |
| 2015 Q1 | 7.9 Million USD | 8.28% |
| 2015 Q4 | 9.3 Million USD | -22.97% |
| 2014 Q1 | 7.6 Million USD | -14.24% |
| 2014 FY | 28.45 Million USD | 0.75% |
| 2014 Q3 | 6.68 Million USD | -2.59% |
| 2014 Q2 | 6.86 Million USD | -9.78% |
| 2014 Q4 | 7.29 Million USD | 9.14% |
| 2013 Q2 | 6.95 Million USD | 0.75% |
| 2013 FY | 28.24 Million USD | -49.5% |
| 2013 Q3 | 5.52 Million USD | -20.6% |
| 2013 Q4 | 8.87 Million USD | 60.7% |
| 2013 Q1 | 6.9 Million USD | -14.69% |
| 2012 Q1 | 20.06 Million USD | -29.44% |
| 2012 FY | 55.93 Million USD | -39.95% |
| 2012 Q4 | 8.08 Million USD | -27.26% |
| 2012 Q3 | 11.12 Million USD | -33.26% |
| 2012 Q2 | 16.66 Million USD | -16.93% |
| 2011 Q4 | 28.42 Million USD | 21.65% |
| 2011 Q1 | 18.65 Million USD | 44.08% |
| 2011 Q2 | 22.68 Million USD | 21.58% |
| 2011 Q3 | 23.37 Million USD | 3.03% |
| 2011 FY | 93.13 Million USD | 160.47% |
| 2010 Q1 | 6.46 Million USD | 367.36% |
| 2010 FY | 35.75 Million USD | 201.98% |
| 2010 Q4 | 12.94 Million USD | 54.24% |
| 2010 Q3 | 8.39 Million USD | 5.63% |
| 2010 Q2 | 7.94 Million USD | 22.92% |
| 2009 FY | 11.84 Million USD | -14.58% |
| 2009 Q4 | 1.38 Million USD | -59.44% |
| 2009 Q3 | 3.41 Million USD | 3.81% |
| 2009 Q2 | 3.28 Million USD | -12.64% |
| 2009 Q1 | 3.76 Million USD | -7.86% |
| 2008 FY | 13.86 Million USD | -47.47% |
| 2008 Q4 | 4.08 Million USD | 44.47% |
| 2008 Q3 | 2.82 Million USD | 0.0% |
| 2007 FY | 26.39 Million USD | 207.58% |
| 2006 FY | 8.58 Million USD | 1460.0% |
| 2005 FY | 550 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | 100.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 100.0% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 100.0% |
| Nascent Biotech, Inc. | 2.22 Million USD | 100.0% |
| Rebus Holdings, Inc. | 664 Thousand USD | 100.0% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 100.0% |
| Qrons Inc. | 643.67 Thousand USD | 100.0% |
| Adynxx, Inc. | - USD | NaN% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 100.0% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 100.0% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 100.0% |
| Skye Bioscience, Inc. | 13.54 Million USD | 100.0% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 100.0% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 100.0% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 100.0% |
| SQZ Biotechnologies Company | 85.61 Million USD | 100.0% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 100.0% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 100.0% |
| Mesoblast Limited | 5.9 Million USD | 100.0% |
| Marizyme, Inc. | 19.23 Million USD | 100.0% |
| Genus plc | 147.7 Million USD | 100.0% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 100.0% |
| Pharming Group N.V. | 225.49 Million USD | 100.0% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 100.0% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 100.0% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 100.0% |
| ContraFect Corporation | 56.88 Million USD | 100.0% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 100.0% |
| Sienna Biopharmaceuticals, Inc. | - USD | NaN% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 100.0% |
| IMV Inc. | 37.7 Million USD | 100.0% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 100.0% |
| MultiCell Technologies, Inc. | 567.42 USD | 100.0% |
| ONE Bio Corp. | 6.44 Million USD | 100.0% |
| Accustem Sciences Inc. | 3.74 Million USD | 100.0% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 100.0% |
| Arno Therapeutics, Inc. | - USD | NaN% |
| EV Biologics, Inc. | 531.96 Thousand USD | 100.0% |
| Q BioMed Inc. | 3.43 Million USD | 100.0% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 100.0% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 100.0% |
| Biomind Labs Inc. | 994.18 Thousand USD | 100.0% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 100.0% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 100.0% |
| TetraLogic Pharmaceuticals Corporation | - USD | NaN% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 100.0% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 100.0% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 100.0% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 100.0% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 100.0% |
| GB Sciences, Inc. | 1.42 Million USD | 100.0% |
| Alpha Cognition Inc. | 9.7 Million USD | 100.0% |
| HST Global, Inc. | 140.9 Thousand USD | 100.0% |
| CSL Limited | 3.44 Billion USD | 100.0% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 100.0% |
| Halberd Corporation | 74.84 Thousand USD | 100.0% |
| Enzolytics Inc. | 2.17 Million USD | 100.0% |
| Agentix Corp. | 1.37 Million USD | 100.0% |
| Resverlogix Corp. | 12.71 Million USD | 100.0% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 100.0% |
| MetaStat, Inc. | - USD | NaN% |
| argenx SE | 1.53 Billion USD | 100.0% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 100.0% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 100.0% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 100.0% |
| GeneThera, Inc. | - USD | NaN% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 100.0% |
| AVAX Technologies, Inc. | 7.31 Million USD | 100.0% |
| Zenith Capital Corp. | 8.94 Million USD | 100.0% |
| Genscript Biotech Corporation | 825.34 Million USD | 100.0% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | 100.0% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 100.0% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 100.0% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 100.0% |
| Kadimastem Ltd | 2.41 Million USD | 100.0% |
| Helix BioMedix, Inc. | 1.97 Million USD | 100.0% |
| VitaSpring Biomedical Co. Ltd. | - USD | NaN% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 100.0% |
| BioStem Technologies, Inc. | 22.97 Million USD | 100.0% |
| Oncology Pharma Inc. | - USD | NaN% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 100.0% |
| LadRx Corporation | 3.81 Million USD | 100.0% |
| Cell Source, Inc. | 4.32 Million USD | 100.0% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 100.0% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 100.0% |
| NovAccess Global Inc. | 2.46 Million USD | 100.0% |
| Affymax, Inc. | 39.38 Million USD | 100.0% |
| Itoco Inc. | 919.14 Thousand USD | 100.0% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 100.0% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 100.0% |
| Mobile Lads Corp. | 554.54 Thousand USD | 100.0% |
| CytoDyn Inc. | 18.05 Million USD | 100.0% |
| Claritas Pharmaceuticals, Inc. | - USD | NaN% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | 100.0% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 100.0% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 100.0% |
| SYBLEU INC | 160.87 Thousand USD | 100.0% |
| Advanced Proteome Therapeutics Corporation | - USD | NaN% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 100.0% |
| International Stem Cell Corporation | 5.27 Million USD | 100.0% |
| Bioxytran, Inc. | 3.82 Million USD | 100.0% |
| GlobeImmune, Inc. | - USD | NaN% |
| Predictive Technology Group, Inc. | - USD | NaN% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 100.0% |
| Cardax, Inc. | - USD | NaN% |
| VG Life Sciences Inc. | 20.34 Thousand USD | 100.0% |
| Kaleido Biosciences, Inc. | - USD | NaN% |
| Advaxis, Inc. | 36.26 Million USD | 100.0% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 100.0% |
| RenovaCare, Inc. | - USD | NaN% |
| Regnum Corp. | 735.83 Thousand USD | 100.0% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 100.0% |
| Neutra Corp. | 243.82 Thousand USD | 100.0% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 100.0% |
| PureTech Health plc | 144.59 Million USD | 100.0% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 100.0% |
| IXICO plc | 4.7 Million USD | 100.0% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 100.0% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 100.0% |
| CSL Limited | 3.89 Billion USD | 100.0% |
| Cellectis S.A. | 97.32 Million USD | 100.0% |